查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
傷口護理生技藥品市場：按產品、傷口類型和最終用戶：全球機會分析和產業預測，2023-2032年
市場調查報告書
商品編碼
1365615

傷口護理生技藥品市場：按產品、傷口類型和最終用戶：全球機會分析和產業預測，2023-2032年

Wound Care Biologics Market By Product, By Wound Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 255 Pages | 商品交期: 2-3個工作天內

價格

由於對傷口護理傷口護理生技藥品的需求不斷增加以及製藥部門研發活動的增加，傷口治療生物製劑市場從2023年到2032年可能會出現 6.1%的顯著成長率 - Allied Market 根據研究報告《傷口護理生技藥品市場》 ResearchAllied Market Research 發布的資料顯示，2022年傷口護理生技藥品市場價值為 18 億美元，2023年至2032年年複合成長率為6.1%，到2032年將達到33億美元。

用於傷口護理的生技藥品是指從活生物體或其結構要素中提取的先進治療產品的開發和製造。這些生物製藥專門用於促進創傷治療、組織再生以及複雜和慢性傷口的治療。傷口護理生技藥品透過傷口管理的效率和有效性實現更快的癒合。

傷口護理生物製劑市場-IMG1

由於糖尿病足潰瘍、腿部靜脈潰瘍、壓瘡等慢性傷口的患病不斷增加，是傷口護理的生技藥品市場成長的關鍵因素。例如，根據美國疾病管制與預防中心（CDC）的國家糖尿病統計報告，到美國，美國將有約3,730萬人患有糖尿病。隨著糖尿病患者數量的不斷增加，糖尿病足潰瘍的風險也在增加，增加了對有效治療方案的需求，包括用於傷口護理的生技藥品。

目錄

第1章 簡介

第2章 執行摘要

第3章 市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響要素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 燒燙傷和交通事故負擔增加
      • 慢性病和手術迅速增加
      • 傷口護理的進展
    • 抑制因素
      • 用於傷口護理的生技藥品價格高
      • 關於創傷護理產品生產的嚴格法規
    • 機會
      • 新興市場的成長機會
  • COVID-19 市場影響分析

第4章 傷口護理生技藥品市場：依產品

  • 概述
  • 生物皮膚替代
    • 生物皮膚替代傷口護理生技藥品市場：依類型
  • 外用藥物

第5章 傷口護理生技藥品市場：依傷口類型

  • 概述
  • 急性傷口
    • 急性傷口傷口護理生技藥品市場：依類型
  • 慢性傷口
    • 慢性傷口傷口護理生技藥品市場：依類型

第6章 傷口護理生技藥品市場：依最終使用者分類

  • 概述
  • 醫院和診所
  • 傷口和燒傷中心
  • 其他

第7章 傷口護理生技藥品市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲、中東、非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第8章 競爭形勢

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Integra LifeSciences Holdings Corporation
  • Kerecis
  • MIMEDX Group, Inc.
  • ORGANOGENESIS HOLDINGS INC.
  • Skye Biologics Holdings, LLC
  • Smith & Nephew plc
  • Stryker Corporation.
  • Tissue Regenix Group Plc
  • ConvaTec Group plc
  • Lavior Pharma Inc.
Product Code: A10347

The Wound Care Biologics Market is likely to experience a significant growth rate of 6.1% from 2023-2032 owing to increase in demand for wound care biologics and increase in research and developmwnt activites from pharmaceutical sector - Allied Market Research. According to a new report published by Allied Market Research, titled, "Wound Care Biologics Market," The wound care biologics market was valued at $1.8 billion in 2022, and is estimated to reach $3.3 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. Wound care biologics refers to development and production of advanced therapeutic products derived from living organisms or their components. These biologic products are specifically designed to promote wound healing, tissue regeneration, and the management of complex or chronic wounds. Wound care biologic products enable faster healing due to their efficiency & effectiveness in managing wounds.

Wound Care Biologics Market - IMG1

The wound care biologics market has experienced significant growth owing to the increase in prevalence of chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, which is a major factor that fosters the wound care biologics market growth. For instance, according to National Diabetes Statistics Report by Centers for Disease Control and Prevention (CDC), 2022, about 37.3 million people are diabetic in the U.S. As the number of people with diabetes continues to grow, so does the risk of developing diabetic foot ulcers, leading to higher demand for effective treatment options including wound care biologics.

In addition, elderly individuals are more prone to chronic wounds thus, the rise in geriatric population drives the demand for wound care biologics and propels market growth. These advanced therapies provide efficient wound healing to this vulnerable population. Moreover, traditional wound care products such as hydrocolloids, hydrogels, film & foam dressings, and alginates are being increasingly replaced with advanced wound care products such as biologics, due to their enhanced effectiveness in managing wounds by enabling rapid healing, which further supports the market growth.

Furthermore, research and development efforts have led to the introduction of innovative wound care biologics with enhanced efficacy and safety profiles. The introduction of novel growth factors, stem cell-based therapies, and tissue-engineered products have expanded the treatment options available, driving market growth. For instance, Organogenesis Holding Inc. company has developed and commercialized a product called Apligraf, which is an advanced tissue-engineered therapy designed for the treatment of chronic wounds. Such advanced products available in the market drive the market growth.

In addition, ongoing research in the field of regenerative medicine, exploring the potential of stem cells, growth factors, and tissue engineering to promote wound healing further support the market growth This surge in investment in research and development activities by pharmaceutical companies, academic institutions, and healthcare organizations has accelerated the discovery of novel therapeutic approaches, fueling the growth of the market.

The wound care biologics market is segmented on the basis of product, wound type, end user, and region. By product, the market is bifurcated into biological skin substitutes and topical agents. The biological skin substitutes segment further classified into human donor tissue derived products, animal derived products, and cell based bioengineered products. By wound type, the market is categorized into acute and chronic. The acute segment is further classified into burns & trauma, and surgical. The chronic segment is further divided into pressure ulcers, diabetic ulcers, venous ulcers, and others. By end user, the market is segregated into hospitals and clinics, wound centers and burn centers, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the wound care biologics market are ConvaTec Group plc, Integra LifeSciences Holdings Corporation, Kerecis, Lavior Pharma Inc., MIMEDX Group, Inc., Organogenesis Holding Inc., Skye Biologics Holdings, LLC, Smith & Nephew plc, Stryker Corporation., Tissue Regenix Group Plc. Key players have adopted product launch, product approval, and acquisition as key developmental strategies to improve the product portfolio of the wound care biologics market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wound care biologics market analysis from 2022 to 2032 to identify the prevailing wound care biologics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the wound care biologics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global wound care biologics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Wound Type

  • Acute Wound
    • Type
    • Burns and Trauma
    • Surgical
  • Chronic Wound
    • Type
    • Pressure Ulcer
    • Diabetic Ulcer
    • Venous Ulcer
    • Others

By End User

  • Hospitals and Clinics
  • Wound Centers and Burn Centers
  • Others

By Product

  • Biological Skin Substitutes
    • Type
    • Human Donor Tissue Derived Products
    • Animal Derived Products
    • Cell Based Bioengineered Products
  • Topical Agents

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Skye Biologics Holdings, LLC
    • Tissue Regenix Group Plc
    • Lavior Pharma Inc.
    • ORGANOGENESIS HOLDINGS INC.
    • Kerecis
    • Smith & Nephew plc
    • Stryker Corporation.
    • MIMEDX Group, Inc.
    • Integra LifeSciences Holdings Corporation
    • ConvaTec Group plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Growing burden of burn injuries and road accidents
      • 3.4.1.2. Surge in incidences of chronic diseases and surgeries
      • 3.4.1.3. Advancements in wound care management
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of wound care biologics
      • 3.4.2.2. Stringent regulations for manufacturing of wound care products
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: WOUND CARE BIOLOGICS MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Biological Skin Substitutes
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Biological Skin Substitutes Wound Care Biologics Market by Type
  • 4.3. Topical Agents
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Acute Wound
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Acute Wound Wound Care Biologics Market by Type
  • 5.3. Chronic Wound
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
    • 5.3.4. Chronic Wound Wound Care Biologics Market by Type

CHAPTER 6: WOUND CARE BIOLOGICS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals and Clinics
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Wound Centers and Burn Centers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: WOUND CARE BIOLOGICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Product
    • 7.2.3. Market size and forecast, by Wound Type
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Product
      • 7.2.5.1.3. Market size and forecast, by Wound Type
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Product
      • 7.2.5.2.3. Market size and forecast, by Wound Type
      • 7.2.5.2.4. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Product
      • 7.2.5.3.3. Market size and forecast, by Wound Type
      • 7.2.5.3.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Product
    • 7.3.3. Market size and forecast, by Wound Type
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Product
      • 7.3.5.1.3. Market size and forecast, by Wound Type
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Product
      • 7.3.5.2.3. Market size and forecast, by Wound Type
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Product
      • 7.3.5.3.3. Market size and forecast, by Wound Type
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Product
      • 7.3.5.4.3. Market size and forecast, by Wound Type
      • 7.3.5.4.4. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Product
      • 7.3.5.5.3. Market size and forecast, by Wound Type
      • 7.3.5.5.4. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Product
      • 7.3.5.6.3. Market size and forecast, by Wound Type
      • 7.3.5.6.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Product
    • 7.4.3. Market size and forecast, by Wound Type
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Product
      • 7.4.5.1.3. Market size and forecast, by Wound Type
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Product
      • 7.4.5.2.3. Market size and forecast, by Wound Type
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Product
      • 7.4.5.3.3. Market size and forecast, by Wound Type
      • 7.4.5.3.4. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Product
      • 7.4.5.4.3. Market size and forecast, by Wound Type
      • 7.4.5.4.4. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Product
      • 7.4.5.5.3. Market size and forecast, by Wound Type
      • 7.4.5.5.4. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Product
      • 7.4.5.6.3. Market size and forecast, by Wound Type
      • 7.4.5.6.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Product
    • 7.5.3. Market size and forecast, by Wound Type
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Product
      • 7.5.5.1.3. Market size and forecast, by Wound Type
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Product
      • 7.5.5.2.3. Market size and forecast, by Wound Type
      • 7.5.5.2.4. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Product
      • 7.5.5.3.3. Market size and forecast, by Wound Type
      • 7.5.5.3.4. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Product
      • 7.5.5.4.3. Market size and forecast, by Wound Type
      • 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Integra LifeSciences Holdings Corporation
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Kerecis
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
  • 9.3. MIMEDX Group, Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. ORGANOGENESIS HOLDINGS INC.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Skye Biologics Holdings, LLC
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Smith & Nephew plc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Stryker Corporation.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Tissue Regenix Group Plc
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. ConvaTec Group plc
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Lavior Pharma Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 02. WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL BIOLOGICAL SKIN SUBSTITUTES WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 06. WOUND CARE BIOLOGICS MARKET FOR ACUTE WOUND, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL ACUTE WOUND WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 08. WOUND CARE BIOLOGICS MARKET FOR CHRONIC WOUND, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL CHRONIC WOUND WOUND CARE BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 11. WOUND CARE BIOLOGICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. WOUND CARE BIOLOGICS MARKET FOR WOUND CENTERS AND BURN CENTERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. WOUND CARE BIOLOGICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. WOUND CARE BIOLOGICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 19. U.S. WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 20. U.S. WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. CANADA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. CANADA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. UK WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 39. UK WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 40. UK WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. ITALY WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. ITALY WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. CHINA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 58. CHINA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. INDIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. INDIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 62. INDIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA WOUND CARE BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 88. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 89. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 90. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT SEGMENTS
  • TABLE 91. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 92. KERECIS: KEY EXECUTIVES
  • TABLE 93. KERECIS: COMPANY SNAPSHOT
  • TABLE 94. KERECIS: PRODUCT SEGMENTS
  • TABLE 95. KERECIS: PRODUCT PORTFOLIO
  • TABLE 96. MIMEDX GROUP, INC.: KEY EXECUTIVES
  • TABLE 97. MIMEDX GROUP, INC.: COMPANY SNAPSHOT
  • TABLE 98. MIMEDX GROUP, INC.: PRODUCT SEGMENTS
  • TABLE 99. MIMEDX GROUP, INC.: PRODUCT PORTFOLIO
  • TABLE 100. MIMEDX GROUP, INC.: KEY STRATERGIES
  • TABLE 101. ORGANOGENESIS HOLDINGS INC.: KEY EXECUTIVES
  • TABLE 102. ORGANOGENESIS HOLDINGS INC.: COMPANY SNAPSHOT
  • TABLE 103. ORGANOGENESIS HOLDINGS INC.: PRODUCT SEGMENTS
  • TABLE 104. ORGANOGENESIS HOLDINGS INC.: PRODUCT PORTFOLIO
  • TABLE 105. SKYE BIOLOGICS HOLDINGS, LLC: KEY EXECUTIVES
  • TABLE 106. SKYE BIOLOGICS HOLDINGS, LLC: COMPANY SNAPSHOT
  • TABLE 107. SKYE BIOLOGICS HOLDINGS, LLC: PRODUCT SEGMENTS
  • TABLE 108. SKYE BIOLOGICS HOLDINGS, LLC: PRODUCT PORTFOLIO
  • TABLE 109. SMITH & NEPHEW PLC: KEY EXECUTIVES
  • TABLE 110. SMITH & NEPHEW PLC: COMPANY SNAPSHOT
  • TABLE 111. SMITH & NEPHEW PLC: PRODUCT SEGMENTS
  • TABLE 112. SMITH & NEPHEW PLC: PRODUCT PORTFOLIO
  • TABLE 113. STRYKER CORPORATION.: KEY EXECUTIVES
  • TABLE 114. STRYKER CORPORATION.: COMPANY SNAPSHOT
  • TABLE 115. STRYKER CORPORATION.: PRODUCT SEGMENTS
  • TABLE 116. STRYKER CORPORATION.: PRODUCT PORTFOLIO
  • TABLE 117. STRYKER CORPORATION.: KEY STRATERGIES
  • TABLE 118. TISSUE REGENIX GROUP PLC: KEY EXECUTIVES
  • TABLE 119. TISSUE REGENIX GROUP PLC: COMPANY SNAPSHOT
  • TABLE 120. TISSUE REGENIX GROUP PLC: PRODUCT SEGMENTS
  • TABLE 121. TISSUE REGENIX GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 122. CONVATEC GROUP PLC: KEY EXECUTIVES
  • TABLE 123. CONVATEC GROUP PLC: COMPANY SNAPSHOT
  • TABLE 124. CONVATEC GROUP PLC: PRODUCT SEGMENTS
  • TABLE 125. CONVATEC GROUP PLC: PRODUCT PORTFOLIO
  • TABLE 126. CONVATEC GROUP PLC: KEY STRATERGIES
  • TABLE 127. LAVIOR PHARMA INC.: KEY EXECUTIVES
  • TABLE 128. LAVIOR PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 129. LAVIOR PHARMA INC.: PRODUCT SEGMENTS
  • TABLE 130. LAVIOR PHARMA INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. WOUND CARE BIOLOGICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF WOUND CARE BIOLOGICS MARKET,2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN WOUND CARE BIOLOGICS MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. GLOBAL WOUND CARE BIOLOGICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2022(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR ACUTE WOUND, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR CHRONIC WOUND, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. WOUND CARE BIOLOGICS MARKET, BY END USER, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR WOUND CENTERS AND BURN CENTERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF WOUND CARE BIOLOGICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. WOUND CARE BIOLOGICS MARKET BY REGION, 2022(%)
  • FIGURE 21. U.S. WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. CANADA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. MEXICO WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. GERMANY WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. FRANCE WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. UK WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. ITALY WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. SPAIN WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. REST OF EUROPE WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. JAPAN WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CHINA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. INDIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SOUTH KOREA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF ASIA-PACIFIC WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. BRAZIL WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SAUDI ARABIA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SOUTH AFRICA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF LAMEA WOUND CARE BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 44. COMPETITIVE DASHBOARD
  • FIGURE 45. COMPETITIVE HEATMAP: WOUND CARE BIOLOGICS MARKET
  • FIGURE 46. TOP PLAYER POSITIONING, 2022
  • FIGURE 47. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. MIMEDX GROUP, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. ORGANOGENESIS HOLDINGS INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. SMITH & NEPHEW PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. SMITH & NEPHEW PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. SMITH & NEPHEW PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. STRYKER CORPORATION.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. STRYKER CORPORATION.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. STRYKER CORPORATION.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. TISSUE REGENIX GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. TISSUE REGENIX GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. CONVATEC GROUP PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. CONVATEC GROUP PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. CONVATEC GROUP PLC: REVENUE SHARE BY REGION, 2022 (%)